

North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 4th September 2024

Classification of products:

G **Green drug** - Can be initiated and prescribed in all care settings **O**- Second line / alternative green drug.

ASR

Amber Specialist Recommendation drug - Can be recommended by a specialist for initiation in primary care.

ASI

Amber Specialist Initiation drug – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.

ASC

Amber Shared Care drug - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care.

R

Red drug - Drugs that should remain under the total responsibility of the specialist. Usually considered as “hospital only” drugs.

BLACK Not Approved - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.

GREY Not Reviewed - Drugs that have not been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.



Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meeting				
None				
2) New Requests				
Viscose garments (e.g. Skinnies, Clinifast, Comifast Easiwrap)	✓ ASI			Decision: approved as AMBER SI for use the management of eczema, psoriasis and Epidermolysis Bullosa and any other skin condition requiring covering.
3) New formulations & extensions to use				
None				
5) Products considered by NICE				
TA979: Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA980: Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA981: Voxelotor for treating haemolytic anaemia caused by sickle cell disease	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA982: Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA983: Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA984: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner. Replaces TA696
TA985: Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA986: Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over	✓ R			The formulary will reflect the TAG – ICB is the responsible commissioner.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA987: Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner. Received for information.
TA988: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner. This guidance updates and replaces TA398 (July 2016).
TA989: Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA990: Tenecteplase for treating acute ischaemic stroke	✓ R			The formulary will reflect the TAG – ICB is the responsible commissioner.
TA992: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy	✓ BLACK			The formulary will reflect the TAG – NHS England is the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Chapter 14 of harmonised NY&Y formulary	✓			
RSV Vaccine (Abrysvo® Pre-F RSV vaccine)	✓ G			Decision: approved for addition to the formulary to support the new national Respiratory syncytial virus (RSV) vaccination programme.
Bupropion for depression	✓ ASI			Decision: Approved a change to the formulary status of bupropion for resistant depression from RED to AMBER-SI to support a consistent formulary position across the patch covered TEWV.
Duloxetine for depression and anxiety	✓ G			Decision: confirmed RAG status for both indications as GREEN as per TEWV guidelines. Previously listed as GREEN for depression but AMBER SI for anxiety.

DECISION SUMMARY

The following documents/guidelines were presented to and approved at the September 2024 meeting of the APC:

- Generic prescribing of eye preparations for HNY population - final guidance.

The following guidelines were presented to and recommended for approval to the HNY IPMOC at the September 2024 meeting of the APC:

- HNY ICB Valproate Medicines for Patients of Child-Bearing Potential.

The following shared care guidelines were presented to and approved at the September 2024 meeting of the APC:

- Nil

The following documents/guidelines were presented to the September 2024 meeting of the APC for comment:

- Bupropion for resistant depression: Information for Primary Care.
- NY&Y APC Azathioprine and mercaptopurine in adults.